Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer

Israel Zighelboim, Jason D. Wright, Feng Gao, Ashley S. Case, L. Stewart Massad, David G. Mutch, Matthew A. Powell, Premal H. Thaker, Eric L. Eisenhauer, David E. Cohn, Fidel A. Valea, Angeles Alvarez Secord, Lynne T. Lippmann, Farrokh Dehdashti, Janet S. Rader

Research output: Contribution to journalArticlepeer-review

56 Scopus citations

Abstract

Objective We evaluated the activity and safety of the combination of topotecan, cisplatin and bevacizumab in patients with recurrent or persistent carcinoma of the cervix. Methods Eligible patients had persistent or recurrent cervical cancer not amenable to curative intent treatment. No prior chemotherapy for recurrence was allowed. Treatment consisted of cisplatin 50 mg/m 2 day 1, topotecan 0.75 mg/m2 days 1, 2 and 3 and bevacizumab 15 mg/kg day 1 every 21 days until disease progression or limiting toxicity. The primary endpoint was progression free survival at 6 months. We explored PET/CT as a potential early indicator of response to therapy. Results Twenty-seven eligible patients received a median of 3 treatment cycles (range, 1-19). Median follow-up was 10 months (range, 1.7-33.4). The 6-month PFS was 59% (80% CI: 46-70%). In 26 evaluable patients, we observed 1 CR (4%; 80% CI: 0.4-14%) and 8 PR (31%; 80% CI: 19-45%) lasting a median of 4.4 months. Ten patients had SD (39%; 80% CI: 25-53%) with median duration of 2.2 months. Median PFS was 7.1 months (80% CI: 4.7-10.1) and median OS was 13.2 months (80% CI: 8.0-15.4). All patients were evaluated for toxicity. Grade 3-4 hematologic toxicity was common (thrombocytopenia 82% leukopenia 74%, anemia 63%, neutropenia 56%). Most patients (78%) required unanticipated hospital admissions for supportive care and/or management of toxicities. Conclusion The addition of bevacizumab to topotecan and cisplatin results in an active but highly toxic regimen. Future efforts should focus on identification of predictive biomarkers of prolonged response and regimen modifications to minimize toxicity.

Original languageEnglish
Pages (from-to)64-68
Number of pages5
JournalGynecologic oncology
Volume130
Issue number1
DOIs
StatePublished - Jul 2013

Keywords

  • Bevacizumab PET/CT
  • Cervical cancer
  • Chemotherapy
  • Cisplatin
  • Topotecan

Fingerprint

Dive into the research topics of 'Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer'. Together they form a unique fingerprint.

Cite this